These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34785582)

  • 21. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
    Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
    Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes.
    Varghese S; Newton R; Ross-Innes CS; Lao-Sirieix P; Krishnadath KK; O'Donovan M; Novelli M; Wernisch L; Bergman J; Fitzgerald RC
    Gastroenterology; 2015 Nov; 149(6):1511-1518.e5. PubMed ID: 26248086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Amsterdam ReBus progressor cohort: identification of 165 Barrett's surveillance patients who progressed to early neoplasia and 723 nonprogressor patients.
    Duits LC; Klaver E; Bureo Gonzalez A; Boerwinkel DF; Ten Kate FJW; Offerhaus GJA; Meijer SL; Visser M; Seldenrijk CA; Krishnadath KK; Schoon EJ; Weusten BLAM; Mallant-Hent RC; Pouw RE; Bergman JJGHM
    Dis Esophagus; 2019 Nov; 32(9):. PubMed ID: 29873685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia.
    Neyaz A; Odze RD; Rickelt S; Nieman LT; Bledsoe JR; Mahadevan KK; Arora K; Jeck WR; Taylor MS; Gala M; Patil DT; Yilmaz OH; Rivera MN; Ting DT; Deshpande V
    Clin Transl Gastroenterol; 2020 Dec; 12(1):e00272. PubMed ID: 33464729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of p53 protein in Barrett's syndrome with malignant transformation.
    Fléjou JF; Potet F; Muzeau F; Le Pelletier F; Fékété F; Hénin D
    J Clin Pathol; 1993 Apr; 46(4):330-3. PubMed ID: 8496390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International development and validation of a classification system for the identification of Barrett's neoplasia using acetic acid chromoendoscopy: the Portsmouth acetic acid classification (PREDICT).
    Kandiah K; Chedgy FJQ; Subramaniam S; Longcroft-Wheaton G; Bassett P; Repici A; Sharma P; Pech O; Bhandari P
    Gut; 2018 Dec; 67(12):2085-2091. PubMed ID: 28970288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.
    Campos VJ; Mazzini GS; Juchem JF; Gurski RR
    J Gastrointest Surg; 2020 Jan; 24(1):8-18. PubMed ID: 31745889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of p53 immunoreactivity in non-neoplastic and neoplastic Barrett's mucosa of the oesophagus: in-depth evaluation in endoscopic mucosal resections.
    Toon C; Allanson B; Leslie C; Acott N; Mirzai B; Raftopoulos S; Kumarasinghe MP
    Pathology; 2019 Apr; 51(3):253-260. PubMed ID: 30826014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescence spectroscopy incorporated in an Optical Biopsy System for the detection of early neoplasia in Barrett's esophagus.
    Boerwinkel DF; Holz JA; Hawkins DM; Curvers WL; Aalders MC; Weusten BL; Visser M; Meijer SL; Bergman JJ
    Dis Esophagus; 2015; 28(4):345-51. PubMed ID: 24602242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus.
    Alnasser S; Agnihotram R; Martel M; Mayrand S; Franco E; Ferri L
    Can J Surg; 2019 Apr; 62(2):93-99. PubMed ID: 30907564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.
    Kim R; Clarke MR; Melhem MF; Young MA; Vanbibber MM; Safatle-Ribeiro AV; Ribeiro U; Reynolds JC
    Dig Dis Sci; 1997 Dec; 42(12):2453-62. PubMed ID: 9440619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
    Bani-Hani K; Martin IG; Hardie LJ; Mapstone N; Briggs JA; Forman D; Wild CP
    J Natl Cancer Inst; 2000 Aug; 92(16):1316-21. PubMed ID: 10944553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
    Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automated cytological detection of Barrett's neoplasia with infrared spectroscopy.
    Old O; Lloyd G; Isabelle M; Almond LM; Kendall C; Baxter K; Shepherd N; Shore A; Stone N; Barr H
    J Gastroenterol; 2018 Feb; 53(2):227-235. PubMed ID: 28501919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses.
    Snyder P; Dunbar K; Cipher DJ; Souza RF; Spechler SJ; Konda VJA
    Dig Dis Sci; 2019 May; 64(5):1089-1097. PubMed ID: 30911864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.